Last updated: February 13, 2026
What is the drug associated with NDC 70677-1042?
NDC 70677-1042 corresponds to Evolocumab, marketed under the brand name Repatha. It is a PCSK9 inhibitor used to reduce low-density lipoprotein cholesterol (LDL-C) levels in patients with hypercholesterolemia and cardiovascular risk.
What is the current market size for Evolocumab?
The global PCSK9 inhibitor market, including Evolocumab, was valued at approximately $4.0 billion in 2022. This segment is projected to grow at a compound annual growth rate (CAGR) of approximately 8% from 2023 to 2030. The growth is driven by increasing awareness of cardiovascular risk management and expanded indications for cholesterol reduction.
How does Evolocumab compare within the PCSK9 inhibitor market?
Evolocumab has competed primarily with Alirocumab (Praluent), forming a duopoly in the PCSK9 market. As of 2022:
| Product |
Market Share |
Price (per year) |
Approved Indications |
| Evolocumab |
~60% |
$14,100 |
Heterozygous familial hypercholesterolemia (HeFH), clinical ASCVD |
| Alirocumab |
~40% |
$14,600 |
Similar indications, slight dosage differences |
Evolocumab's higher market penetration has been sustained through pricing strategies and formulary access.
What are the drivers of pricing and revenue?
Pricing Factors:
- List Price: Approximately $14,100 annually per patient.
- Contract Negotiations: With PBMs and payers, actual prices may vary downward.
- Patent Life: Patent expiry potential influences future price adjustments.
Revenue Drivers:
- Prescriptions: Estimated 250,000 to 300,000 annually in the U.S. alone.
- Indication Expansion: Recent approvals for additional patient populations could increase market size.
- Competitive Dynamics: Entry of biosimilars or generic versions may pressure prices starting mid-2020s.
What is the forecasted price trajectory?
| Year |
Price per Patient |
Notes |
| 2023 |
$14,000 – $14,200 |
Pricing stabilized after negotiation shifts |
| 2025 |
$13,500 – $14,000 |
Potential discounts due to increased biosimilar activity |
| 2030 |
$12,000 – $13,000 |
Continued pressure from biosimilar competition |
Expected price reductions stem from biosimilar developments and increased payer negotiation leverage. Price erosion of 2-4% annually is a conservative baseline.
How might biosimilars impact the market?
Biosimilar versions of Evolocumab could reach the U.S. market by 2024–2025, potentially reducing prices by 20–30%. This could diminish revenue per patient and aggregate market size, though overall adoption could expand due to affordability.
Are there regional variations?
Yes. In Europe, prices tend to be lower than in the U.S., with average annual costs around €10,000–€12,000, influenced by national reimbursement policies. Emerging markets may see significantly lower prices, affecting global revenue projections.
What are the regulatory and patent considerations?
- Patent protections expire around 2028–2030.
- Regulatory pathways for biosimilars are established, with FDA-approved biosimilars already in development.
- Market entry of biosimilars is likely to accelerate price declines and market competition.
Summary of key assumptions and projections:
| Assumption |
Impact on Price/Market |
| Biosimilar entry |
Drives prices down 20–30% from 2024–2025 |
| Patent expiry |
Opens pathway for biosimilar competition, reducing pricing |
| Increased indications |
Expands market size, potentially offsetting price erosion |
| Payer negotiation strength |
Can maintain higher prices with favorable formulary placement |
Key Takeaways
- The market for Evolocumab is valued at ~$4 billion, growing at approximately 8% CAGR.
- Current annual list prices are around $14,100, but future prices are expected to decline due to biosimilar competition.
- Patent expiries around 2028–2030 will significantly impact pricing and market share.
- Price reductions of 20–30% are likely within 2–3 years after biosimilar approval.
- Regional differences influence pricing, with the U.S. maintaining higher rates than Europe or emerging markets.
5 Frequently Asked Questions
1. What factors influence the pricing of Evolocumab?
Pricing is affected by negotiation with payers, biosimilar entry, patent status, and regional reimbursement policies.
2. When are biosimilars expected to enter the market?
Biosimilars are anticipated around 2024–2025, post patent expiry, reducing the drug's cost.
3. How does market penetration vary across regions?
Higher in the U.S., driven by insurance coverage; lower in Europe and emerging markets due to price controls and reimbursement issues.
4. Will expanding indications boost revenue despite pricing pressures?
Yes; increasing treated patient populations can counteract per-unit price reductions.
5. What is the outlook for long-term pricing?
Prices are expected to trend downward, stabilized by biosimilar competition and market saturation, with a potential floor around $10,000 per year in key markets.
References
[1] MarketWatch, "Global PCSK9 Inhibitors Market Size, Share & Trends," 2022.
[2] IQVIA, "Prescription Data and Market Dynamics," 2022.
[3] FDA, "Biosimilar Regulatory Pathway," 2021.
[4] Evaluate Pharma, "Pharmaceutical Pricing Trends," 2022.
